Press Releases

Chronic Lower Back Pain Market Size Scale at USD 6.12 Billion by 2033

The chronic lower back pain market was valued at US$ 2.46 billion in 2023 and is predicted to reach US$ 6.12 billion by the end of 2033, representing an impressive CAGR of 9.52% from 2024 to 2033. The increasing geriatric population with arthritis is one of the leading causes of chronic lower back pain, which is driving the market’s growth.

Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5156

Key Takeaways/ Important Points to Note

  • North America has held a largest revenue share of 48.12% in 2023.
  • By drug class, the non-steroidal anti-inflammatory drugs segment has contributed more than 26% of revenue share in 2023.
  • By drug class, the opioids segment held the second-largest share of the market and is expected to grow at the fastest rate during the forecast period.
  • By route of administration, the oral segment dominated the chronic lower back pain market in 2023.
  • By route of administration, the topical segment is growing significantly in the market.
  • By distribution channel, the retail & online segment dominated the chronic lower back pain market in 2023.

Industry at a Glance

The chronic lower back pain market deals with all the aspects associated with chronic lower back pain, which includes research & development, development of medication, disease monitoring, treatment, and post-treatment care. Even after an original injury or underlying cause of acute low back pain has been addressed, lower back pain that persists for more than 12 weeks or three months is referred to as chronic low back pain (CLBP). In the past ten years, the frequency of CLBP in adults has climbed by over 100%, and as the population ages, it will continue to rise sharply, impacting men and women of all ethnic backgrounds. Some of the main reasons for lower back pain are age, smoking, heredity, degree of fitness, weight increase, and occupational variables, in addition to mental health issues. Healthcare facilities, drug manufacturers, pharmacies, academic institutions, research centers, and assisted living facilities all play a role in the expansion of the chronic lower back pain market.

Top Companies of the Chronic Lower Back Pain Market

  • SpineThera Inc. (U.S.)
  • Pfizer Inc (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Johnson & Johnson Private Limited (U.S.)
  • Medtronic (Ireland)
  • Endo Pharmaceuticals Inc. (Ireland)
  • Sanofi (France)
  • Merck & Co Inc. (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • Vertebral Technologies, Inc. (U.S.)
  • Boston Scientific Corporation (U.S.)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Astellas Pharma Inc. (Japan)
  • CELGENE CORPORATION (U.S.)

Segments Covered in Chronic Lower Back Pain Market Report

By Drug Class

  • Non-steroidal Anti-inflammatory Drugs
  • Antidepressants
  • Analgesic
  • Opioids
  • Others

By Route of Administration

  • Oral
  • Topical
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field –  https://www.towardshealthcare.com/table-of-content/chronic-lower-back-pain-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5156

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.

Recent Posts

WhiteGlove Launches End-to-End Concierge Healthcare Platform for Elderly Care

India, September 2024 — WhiteGlove, an innovative concierge healthcare platform, has announced the launch of its services aimed at providing… Read More

1 day ago

Generic Pharmaceuticals Market Import/Export Data (Sept 2023 – 2024)

Between September 2023 and September 2024, several prominent pharmaceutical companies recorded significant shipment volumes. These shipments, often comprising medicines or… Read More

1 day ago

U.S. Exosomes Market Size to Reach USD 1,428.79 Mn by 2033

The U.S. exosomes market was valued at US$ 75.30 million in 2023 and is projected to reach US$ 1,428.79 million… Read More

2 weeks ago

Catheter Related Bloodstream Infection Market Size (USD 2.52 Bn) by 2033

The catheter related bloodstream infection market was valued at US$ 1.53 billion in 2023 and is predicted to reach US$… Read More

2 weeks ago

Chronic Obstructive Pulmonary Disease (COPD) Market Size (USD 33.29 Bn) by 2033

The chronic obstructive pulmonary disease market size was valued at US$ 21.6 billion in 2023 and is predicted to reach… Read More

2 weeks ago

Non-Small Lung Carcinoma Market Size Boost at USD 21.51 Billion by 2033

The non-small lung carcinoma market was valued at US$ 8.27 billion in 2023 and is predicted to reach US$ 21.51… Read More

2 weeks ago